Running a ALT wheel strategy lets you generate consistent premium income on Altimmune Inc while setting your own entry and exit prices on the underlying. Altimmune Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own ALT, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best ALT wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on ALT, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable ALT wheel from a losing one.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc.
in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the ALT wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your ALT wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
